Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Research article

Levels and predictors of participation in integrated treatment programs for pregnant and parenting women with problematic substance use

Authors: Thao Lan Le, Chris Kenaszchuk, Karen Milligan, Karen Urbanoski

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

Women who are seeking services for problematic substance use are often also balancing responsibilities of motherhood. Integrated treatment programs were developed to address the diverse needs of women, by offering a holistic and comprehensive mix of services that are trauma- and violence-informed, and focus on maternal and child health promotion and the development of healthy relationships.

Methods

Using system-level administrative data from a suite of outpatient integrated programs in Ontario, Canada, we described the clients and rates and predictors of treatment participation over a 7-year period (2008–2014; N = 5162).

Results

All participants were either pregnant or parenting children under 6 years old at admission to treatment. Retention (length of time between the first and last visit) averaged 124.9 days (SD = 185.6), with episodes consisting of 14.6 visits (SD = 28.6). The vast majority of women attended more than one visit (87.2%), typically returning within 2 weeks (mean 12.3 days, SD = 11.1). In addition to being pregnant or new mothers experiencing problematic substance use, most were unemployed, on social assistance, and single.

Conclusions

Programs appeared to be able to successfully engage most women in treatment once they accessed the programs. Although rates of treatment participation did vary across subgroups defined by sociodemographic and admission characteristics, effect sizes tended to be small on average, providing little evidence in general of sociodemographic inequities in participation. Further work is needed to study the influence of program-level factors on participation, and how these link to maternal and child outcomes.
Literature
1.
Milligan K, Niccols A, Sword W, Thabane L, Henderson J, Smith A. Length of stay and treatment completion for mothers with substance abuse issues in integrated treatment programmes. Drugs: education, prevention and policy. 2011;18(3):219–27.
2.
Brady TM, Ashley OS. Women in substance abuse treatment: results from the alcohol and drug services study (ADSS) (DHHS publication no. SMA 04-3968, analytic series A-26). Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2005.
3.
Pelissier B, Jones N. A review of gender differences among substance abusers. Crime Delinq. 2005;51(3):343–72.CrossRef
4.
Finkelstein N. Treatment issues for alcohol- and drug-dependent pregnant and parenting women. Health Soc Work. 1994;19(1):7–15.PubMedCrossRef
5.
Grella CE. Services for perinatal women with substance abuse and mental health disorders: the unmet need. J Psychoactive Drugs. 1997;29(1):67–78.PubMedCrossRef
6.
Schober R, Annis HM. Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Addict Behav. 1996;21(1):81–92.PubMedCrossRef
7.
Finnegan L. Substance abuse in Canada: licit and illicit drug use during pregnancy: maternal, neonatal and early childhood consequences. Ottawa, ON: Canadian Centre on Subst Abus. 2013.
8.
Hume L, Bradley N. In: Poole Na GL, editor. Highs and lows: Canadian perspectives on women and substance use. Toronto: Centre for Addiction and Mental Health; 2007.
9.
Milligan K, Niccols A, Sword W, Thabane L, Henderson J, Smith A, et al. Maternal substance use and integrated treatment programs for women with substance abuse issues and their children: a meta-analysis. Subst Abuse Treat Prev Policy. 2010;5:21.PubMedPubMedCentralCrossRef
10.
Health Canada. Best practices: early intervention, Outreach and Community Linkages for Women with Substance Use Problems Health Canada; 2006.
11.
Milligan K, Niccols A, Sword W, Thabane L, Henderson J, Smith A. Birth outcomes for infants born to women participating in integrated substance abuse treatment programs: a meta-analytic review. Addict Res Theory. 2011;19(6):542–55.CrossRef
12.
Niccols A, Milligan K, Sword W, Thabane L, Henderson J, Smith A. Integrated programs for mothers with substance abuse issues: a systematic review of studies reporting on parenting outcomes. Harm Reduct J. 2012;9:14.PubMedPubMedCentralCrossRef
13.
Niccols A, Milligan K, Smith A, Sword W, Thabane L, Henderson J. Integrated programs for mothers with substance abuse issues and their children: a systematic review of studies reporting on child outcomes. Child Abuse Negl. 2012;36(4):308–22.PubMedCrossRef
14.
Behnke M, Smith VC. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131(3):e1009.PubMedCrossRef
15.
Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47(3):227–35.PubMedCrossRef
16.
Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55(7):767–74.PubMedCrossRef
17.
Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673–84.PubMedCrossRef
18.
Garnick DW, Lee MT, Horgan C, Acevedo A, Botticelli M, Clark S, et al. Lessons from five states: public sector use of the Washington circle performance measures. J Subst Abus Treat. 2011;40(3):241–54.CrossRef
19.
Harris AHS, Kivlahan DR, Bowe T, Finney JW, Humphreys K. Developing and validating process measures of health care quality an application to alcohol use disorder treatment. Med Care. 2009;47(12):1244–50.PubMedCrossRef
20.
Simpson DD. A conceptual framework for drug treatment process and outcomes. J Subst Abus Treat. 2004;27(2):99–121.CrossRef
21.
McCarty D, Gustafson DH, Wisdom JP, Ford J, Choi D, Molfenter T, et al. The network for the improvement of addiction treatment (NIATx): enhancing access and retention. Drug Alcohol Depend. 2007;88(2–3):138–45.PubMedCrossRef
22.
Lee MT, Garnick DW, O'Brien PL, Panas L, Ritter GA, Acevedo A, et al. Adolescent treatment initiation and engagement in an evidence-based practice initiative. J Subst Abus Treat. 2012;42(4):346–55.CrossRef
23.
Acevedo A, Garnick DW, Dunigan R, Horgan CM, Ritter GA, Lee MT, et al. Performance measures and racial/ethnic disparities in the treatment of substance use disorders. J Stud Alcohol Drugs. 2015;76(1):57–67.PubMedPubMedCentralCrossRef
24.
Garnick DW, Horgan CM, Chalk M. Performance measures for alcohol and other drug services. Alcohol Res Health. 2006;29(1):19–26.PubMed
25.
McCarty D, Gustafson D, Capoccia VA, Cotter F. Improving care for the treatment of alcohol and drug disorders. J Behav Health Serv Res. 2009;36(1):52–60.PubMedCrossRef
26.
Brecht ML, Greenwell L, Anglin MD. Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002). J Subst Abus Treat. 2005;29(4):295–306.CrossRef
27.
Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33(8):1010–24.PubMedCrossRef
28.
Campbell CI, Weisner C, Sterling S. Adolescents entering chemical dependency treatment in private managed care: ethnic differences in treatment initiation and retention. J Adolesc Health. 2006;38(4):343–50.PubMedCrossRef
29.
Krawczyk N, Feder KA, Saloner B, Crum RM, Kealhofer M, Mojtabai R. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. Drug Alcohol Depend. 2017;175:157–63.PubMedPubMedCentralCrossRef
30.
Mennis J, Stahler GJ. Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances. J Subst Abus Treat. 2016;63:25–33.CrossRef
31.
Mertens JR, Weisner CM. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin Exp Res. 2000;24(10):1525–33.PubMedCrossRef
32.
Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2–3):188–96.PubMedCrossRef
33.
Lloyd C. The stigmatization of problem drug users: a narrative literature review. Drugs: Education, Prevention and Policy. 2013;20(2):85–95.
34.
Tarasoff LA, Milligan K, Le TL, Usher AM, Urbanoski K. Integrated treatment programs for pregnant and parenting women with problematic substance use: service descriptions and client perceptions of care. J Subst Abus Treat. 2018;90:9–18.CrossRef
35.
Meixner T, Milligan K, Urbanoski K, McShane K. Conceptualizing integrated service delivery for pregnant and parenting women with addictions: defining key factors and processes. Canadian Journal of Addiction. 2016;7(3):57–65.
36.
McGuire M, et al. Early childhood development initiative: final evaluation report. Toronto: Cathexis Consulting Inc.; 2006.
37.
Niccols A, Sword W. “New choices” for substance-using mothers and their children: preliminary evaluation. J Subst Abus. 2009;10(4):239–51.
38.
Milligan K, Usher AM, Urbanoski KA. Supporting pregnant and parenting women with substance-related problems by addressing emotion regulation and executive function needs. Addict Res Theory. 2017;25(3):251–61.CrossRef
39.
Ogborne AC, Braun K, Rush BR. Developing an integrated information system for specialized addiction treatment agencies. J Behav Health Serv Res. 1998;25(1):100–7.PubMedCrossRef
40.
Oracle. UTL_MATCH Oracle (R) Database PL/SQL Packages and Types Reference 11g Release 112 2010.
41.
Garnick DW, Lee MT, Horgan CM, Acevedo A. Washington circle public sector W. Adapting Washington circle performance measures for public sector substance abuse treatment systems. J Subst Abus Treat. 2009;36(3):265–77.CrossRef
42.
Atkins DC, Baldwin SA, Zheng C, Gallop RJ, Neighbors C. A tutorial on count regression and zero-altered count models for longitudinal substance use data. Psychol Addict Behav. 2013;27(1):166–77.PubMedCrossRef
43.
Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull. 1995;118(3):392–404.PubMedCrossRef
44.
Bates ME, Buckman JF, Nguyen TT. A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev. 2013;23(1):27–47.PubMedPubMedCentralCrossRef
45.
Verdejo-Garcia A, Betanzos-Espinosa P, Lozano OM, Vergara-Moragues E, Gonzalez-Saiz F, Fernandez-Calderon F, et al. Self-regulation and treatment retention in cocaine dependent individuals: a longitudinal study. Drug Alcohol Depend. 2012;122(1–2):142–8.PubMedCrossRef
46.
Poole N, Isaac B. Apprehensions: Barriers to treatment for substance-using mothers. Vancouver, BC: British Columbia Centre of Excellence for Women's Health. 2001.
47.
Benoit C, Stengel C, Marcellus L, Hallgrimsdottir H, Anderson J, MacKinnon K, et al. Providers’ constructions of pregnant and early parenting women who use substances. Sociol Health Illn. 2014;36(2):252–63.PubMedCrossRef
48.
Chandler A, Whittaker A, Cunningham-Burley S, Williams N, McGorm K, Mathews G. Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods. Int J Drug Policy. 2013;24(6):e35–42.PubMedCrossRef
49.
Grella CE, Hser YI, Huang YC. Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services. Child Abuse Negl. 2006;30(1):55–73.PubMedCrossRef
50.
Erekson DM, Lambert MJ, Eggett DL. The relationship between session frequency and psychotherapy outcome in a naturalistic setting. J Consult Clin Psychol. 2015;83(6):1097–107.PubMedCrossRef
51.
Centre for Applied Research in Mental Health and Addictions. Cognitive Behavioural Therapy: Core information document. Vancouver, BC: Simon Fraser University; 2007.
52.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.PubMedPubMedCentralCrossRef
53.
McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, et al. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Am J Addict. 2013;22(1):18–22.PubMedPubMedCentralCrossRef
54.
Santonja-Gómez F-J, Sánchez-Hervás E, Secades-Villa R, Zacarés-Romaguera F, García-Rodríguez O, García-Fernández G. Pretreatment characteristics as predictors of retention in cocaine-dependent outpatients. Addictive Disorders & Their Treatment. 2010;9(2):93–8.CrossRef
55.
Stark M. Dropping out of substance abuse treatment: a clinically oriented review. Clin Psychol Rev. 1992;12:93–116.CrossRef
56.
Pulford J, Wheeler A. Documenting client attendance norms: raw data and implications for treatment practice. J Subst Abus. 2007;12(2):95–102.
57.
Garnick DW, Horgan CM, Lee MT, Panas L, Ritter GA, Davis S, et al. Are Washington circle performance measures associated with decreased criminal activity following treatment? J Subst Abus Treat. 2007;33(4):341–52.CrossRef
58.
Chen HN, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Commun Stat-Simul C. 2010;39(4):860–4.CrossRef
59.
Shahram SZ, Bottorff JL, Kurtz DLM, Oelke ND, Thomas V, Spittal PM, et al. Understanding the life histories of pregnant-involved young aboriginal women with substance use experiences in three Canadian cities. Qual Health Res. 2017;27(2):249–59.PubMedCrossRef
60.
Shahram SZ, Bottorff JL, Oelke ND, Kurtz DLM, Thomas V, Spittal PM, et al. Mapping the social determinants of substance use for pregnant-involved young aboriginal women. Int J Qual Stud Heal. 2017:12.
61.
Niccols A, Dobbins M, Sword W, Smith A, Henderson J, Milligan K. A National Survey of Services for Women with substance use issues and their children in Canada: challenges for knowledge translation. Int J Ment Heal Addict. 2010;8(2):310–9.CrossRef
62.
Bloomfield K, Gmel G, Neve R, Mustonen H. Investigating gender convergence in alcohol consumption in Finland, Germany, the Netherlands, and Switzerland: a repeated survey analysis. Subst Abus. 2001;22(1):39–53.PubMed
63.
Keyes KM, Grant BF, Hasin DS. Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. Drug Alcohol Depend. 2008;93(1–2):21–9.PubMedCrossRef
64.
McPherson M, Casswell S, Pledger M. Gender convergence in alcohol consumption and related problems: issues and outcomes from comparisons of New Zealand survey data. Addiction. 2004;99(6):738–48.PubMedCrossRef
65.
Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, et al. Cross-national associations between gender and mental disorders in the World Health Organization world mental health surveys. Arch Gen Psychiatry. 2009;66(7):785–95.PubMedPubMedCentralCrossRef
66.
Steingrimsson S, Carlsen HK, Sigfusson S, Magnusson A. The changing gender gap in substance use disorder: a total population-based study of psychiatric in-patients. Addiction. 2012;107(11):1957–62.PubMedCrossRef
67.
68.
Weisner C, Lu Y, Hinman A, Monahan J, Bonnie RJ, Moore CD, et al. Substance use, symptom, and employment outcomes of persons with a workplace mandate for chemical dependency treatment. Psychiatr Serv. 2009;60(5):646–54.PubMedPubMedCentralCrossRef
69.
Stevens A, Berto D, Heckmann W, Kerschl V, Oeuvray K, van Ooyen M, et al. Quasi-compulsory treatment of drug dependent offenders: an international literature review. Subst Use Misuse. 2005;40(3):269–83.PubMedCrossRef
70.
Beynon CM, Bellis MA, McVeigh J. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the north west of England. BMC Public Health. 2006;6:205.PubMedPubMedCentralCrossRef
71.
Knight DK, Hood PE, Logan SM, Chatham LR. Residential treatment for women with dependent children: one agency's approach. J Psychoactive Drugs. 1999;31(4):339–51.PubMedCrossRef
Metadata
Title
Levels and predictors of participation in integrated treatment programs for pregnant and parenting women with problematic substance use
Authors
Thao Lan Le
Chris Kenaszchuk
Karen Milligan
Karen Urbanoski
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-6455-4

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue

Research article

Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique

Research article

Whole systems approaches to obesity and other complex public health challenges: a systematic review

Research article

Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China

Research article

HIV-positive clients of female sex workers in Hunan Province, China: a mixed methods study assessing sexual relationships and risk behavior by type of partner

Research article

Cybervictimization among secondary students: social networking time, personality traits and parental education

Research article

A health care labyrinth: perspectives of caregivers on the journey to accessing timely cancer diagnosis and treatment for children in India